| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| Monsanto Company |
| 800 North Lindbergh Boulevard, St. Louis, MO 63167 * (314) 694-1000 |
| Business Description | The Company is a leading global provider of technology-based solutions agricultural products for growers and downstream customers. |
| Offering Information Company has | ||||
| Trading As | MON (NYSE) | Industry | Manufacturing (SIC 2879) | |
| Type of Stock Offered | Common Shares | Filing Date | 5/12/00 | |
| Domestic Shares Offered | 35,000,000 | Offer Date | 10/17/00 | |
| Foreign Shares Offered | 0 | Filing Range | $21.00 - $24.00 | |
| Company Shares | 35,000,000 | Offer Price | $20.00 | |
| Selling Shrhldrs Shares | 0 | Gross Spread | $1.000 | |
| Gross Proceeds | $700,000,000 | Selling | $0.600 | |
| Expenses | - - | Reallowance | $0.100 | |
| Post-IPO Shares | 255,000,000 | Employees | - - | |
| Spun out from: | Pharmacia Corporation | |||
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Goldman, Sachs & Co. | Lead Manager | (212) 902-5959 |
| J.P. Morgan & Co. | Co-manager | (212) 648-0517 |
| Merrill Lynch & Co. | Co-manager | (212) 449-4600 |
| Salomon Smith Barney | Co-manager | (212) 723-7300 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | - - Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/95 | 12/31/96 | 12/31/97 | 12/31/98 | 12/31/99 | ||
| Revenues | 2,429.000 | 2,928.000 | 3,673.000 | 4,448.000 | 5,248.000 | - | - |
| Income from Oper. | 512.000 | 506.000 | 13.000 | 55.000 | 625.000 | - | - |
| Net Income | 365.000 | 319.000 | 31.000 | -125.000 | 150.000 | - | - |
| E.P.S | - | - | - | - | - | - | - |
| Revenue Growth (%) | 20.54 | 25.44 | 21.10 | 17.986 | - | ||
| Net Income Growth (%) | -12.60 | -90.28 | - | - | - | ||
| Oper. Profit Margin (%) | 21.08 | 17.28 | 0.35 | 1.24 | 11.91 | - | - |
| Net Profit Margin (%) | 15.03 | 10.89 | 0.84 | - | 2.86 | - | - |
| Cash Flow - Oper. | - | - | - | ||||
| Cash Flow - Inv. | - | - | - | ||||
| Cash Flow - Fin. | - | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 12/31/99 | Financial Ratios | ||||
| Total Assets | 11,101.00 | Current Assets | 4,027.00 | Current Ratio | 2.36 |
| Total Liab. | 6,456.00 | Current Liab. | 1,704.00 | Debt Ratio | 58.16% |
| Total Equity | 4,645.00 | Working Cap. | 2,323.00 | Debt to Equity Ratio | 1.39 |
| Cash | 26.00 | Return on Assets | 1.35% | ||
| Use Of Proceeds |
We expect to use the estimated net proceeds from this offering to pay off a substantial portion of the commercial paper obligations issued by Pharmacia that are to be assumed by Monsanto. If the overallotment option is exercised, we expect to usethe estimated additional net proceeds to reduce further such commercial paper obligations. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Wachtell, Lipton, Rosen & Katz |
| Bank's Law Firm | Cravath, Swaine & Moore |
| Auditor | Deloitte & Touche |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |